{"title":"垂体前腺瘤的糖代谢。","authors":"Valeria Hernández-Brito , Stephanie Lemoni Casco-Morales , Andrés Vega-Rosas","doi":"10.1016/j.cca.2025.120587","DOIUrl":null,"url":null,"abstract":"<div><div>Glucose metabolism alterations are frequently observed in patients with secretory pituitary adenomas. The most commonly secreted hormones in these tumors include prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), all of which can disrupt glucose homeostasis through distinct pathophysiological mechanisms. Prolactin stimulates pancreatic β-cell proliferation, enhances insulin gene transcription, increases intracellular insulin content, and augments glucose-induced insulin secretion. GH promotes lipolysis and hepatic glucose production while impairing peripheral glucose uptake, contributing to insulin resistance. ACTH, via excess glucocorticoids, reduces GLUT-4 translocation, enhances gluconeogenesis and proteolysis, and inhibits glycogen synthesis. Excessive TSH leads to increased T3 and T4 production, which in turn stimulate glucose uptake in muscle and enhance both glycolysis and gluconeogenesis. This review summarizes the current understanding of how hormone hypersecretion in pituitary adenomas contributes to glucose metabolism dysregulation.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120587"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glucose metabolism in anterior pituitary adenomas\",\"authors\":\"Valeria Hernández-Brito , Stephanie Lemoni Casco-Morales , Andrés Vega-Rosas\",\"doi\":\"10.1016/j.cca.2025.120587\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Glucose metabolism alterations are frequently observed in patients with secretory pituitary adenomas. The most commonly secreted hormones in these tumors include prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), all of which can disrupt glucose homeostasis through distinct pathophysiological mechanisms. Prolactin stimulates pancreatic β-cell proliferation, enhances insulin gene transcription, increases intracellular insulin content, and augments glucose-induced insulin secretion. GH promotes lipolysis and hepatic glucose production while impairing peripheral glucose uptake, contributing to insulin resistance. ACTH, via excess glucocorticoids, reduces GLUT-4 translocation, enhances gluconeogenesis and proteolysis, and inhibits glycogen synthesis. Excessive TSH leads to increased T3 and T4 production, which in turn stimulate glucose uptake in muscle and enhance both glycolysis and gluconeogenesis. This review summarizes the current understanding of how hormone hypersecretion in pituitary adenomas contributes to glucose metabolism dysregulation.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"578 \",\"pages\":\"Article 120587\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125004668\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125004668","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Glucose metabolism alterations are frequently observed in patients with secretory pituitary adenomas. The most commonly secreted hormones in these tumors include prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), all of which can disrupt glucose homeostasis through distinct pathophysiological mechanisms. Prolactin stimulates pancreatic β-cell proliferation, enhances insulin gene transcription, increases intracellular insulin content, and augments glucose-induced insulin secretion. GH promotes lipolysis and hepatic glucose production while impairing peripheral glucose uptake, contributing to insulin resistance. ACTH, via excess glucocorticoids, reduces GLUT-4 translocation, enhances gluconeogenesis and proteolysis, and inhibits glycogen synthesis. Excessive TSH leads to increased T3 and T4 production, which in turn stimulate glucose uptake in muscle and enhance both glycolysis and gluconeogenesis. This review summarizes the current understanding of how hormone hypersecretion in pituitary adenomas contributes to glucose metabolism dysregulation.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.